Jeliazko A.
- Country
- Bulgaria
- Department
- Clinic of Medical Oncology
Research Overview
- Comparison of Sotorasib Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in PD-L1 Negative KRAS p.G12C Positive Advanced Non-Squamous NSCLC
- Phase III Trial of BI 764532 Plus Atezolizumab, Carboplatin, and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Durvalumab with Gemcitabine and Cisplatin in First-Line Advanced Biliary Tract Cancer
Data & Insights
Has run more than one trial at 289 of 596 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in treating metastatic hormone-sensitive prostate cancer, with particular emphasis on cases involving PTEN deficiency. Their research encompasses innovative therapeutic combinations including androgen deprivation therapy (ADT) and novel targeted treatments.
- High tumor load prostate cancer management
- PTEN-deficient cancer pathways
- Advanced hormone therapy approaches
Breast Cancer Treatment
The investigator focuses on treating ER-positive/HER2-negative breast cancer in both early and advanced stages. Their expertise extends to managing cases with ESR1 mutations and developing extended therapy protocols for improved patient outcomes.
- Advanced metastatic breast cancer
- Endocrine therapy resistance
- CDK4/6 inhibitor combinations
Colorectal Cancer Studies
Research interests include the treatment of BRAF V600E-mutant metastatic colorectal cancer. The investigator explores combination therapeutic approaches using targeted therapies and standard chemotherapy protocols.
- BRAF-mutant cancer treatment
- Combined therapy approaches
- Advanced colorectal cancer management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.